Nippon Shinyaku licenses Japanese rights to Lilly

Japanese mid-sized drugmaker Nippon Shinyaku has agreed to develop in its home market US drug major Eli Lilly's erectile  dysfunction Cialis (tadalafil). In addition, the two firms will  co-market tadalafil as a treatment for benign prostatic hyperplasia, an  indication for which it is in Phase II trials in Japan and elsewhere.  Nippon will also exclusively market the compound as a treatment for  pulmonary arterial hypertension after obtaining an approval of the drug  from Japanese regulators. A New Drug Application for PAH was submitted  in August 2008.